24 research outputs found
Diet in chronic kidney disease in a Mediterranean African country
No full textAbstract
Background
Mediterranean diet is characterized by low to moderate consumption of animal protein and high consumption of fruits, vegetables, bread, beans, nuts, seeds and other cereals. It has been associated with reduced risk of cardiovascular disease. However, it is not suitable for chronic kidney disease because of high potassium intake.
Discussion
Tunisia is an emerging Mediterranean country with limited resources, a high prevalence of chronic hemodialysis treatment and high dialysis expenditures. In order to limit dialysis cost, primary and secondary prevention of chronic renal disease are of paramount importance. In addition to drugs, secondary prevention includes diet measures (e.g. salt diet, protein diet). The aims of diet practice in chronic kidney disease are to slow chronic renal failure progression and to prevent its complications like hyperphosphatemia and hyperkaliemiae. A few decades ago, a Tunisian diet was exclusively Mediterranean, and protein consumption was not excessive. However, today, protein consumption is more comparable to western countries. Salt consumption is also excessive. Some Tunisian diets still include food with high potassium intake, which are not suitable for patients with chronic kidney disease. Therefore, the role of the dietician is extremely important to help calculate and create a dietary regimen tailored to each of our patients.
Summary
Advice about diets should be adapted to both the patient and population habits to improve adherence rate. As such, the purpose of this article is to provide our own experience regarding medical nutrition therapy in patients with chronic kidney disease in Tunisia, with some changes in food habits. Prevention is far better than treatment. In this perspective, dietary measures must be at the core of our intervention
The Role of SodiumGlucose Cotransporter2 Inhibitors in the Treatment Paradigm of CKD in Africa An African Association of Nephrology Panel Position Paper
No full textOutcomes of male patients with alport syndrome undergoing renal replacement therapy
No full textItem does not contain fulltextBACKGROUND AND OBJECTIVES: Patients with the hereditary disease Alport syndrome commonly require renal replacement therapy (RRT) in the second or third decade of life. This study compared age at onset of RRT, renal allograft, and patient survival in men with Alport syndrome receiving various forms of RRT (peritoneal dialysis, hemodialysis, or transplantation) with those of men with other renal diseases. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with Alport syndrome receiving RRT identified from 14 registries in Europe were matched to patients with other renal diseases. A linear spline model was used to detect changes in the age at start of RRT over time. Kaplan-Meier method and Cox regression analysis were used to examine patient and graft survival. RESULTS: Age at start of RRT among patients with Alport syndrome remained stable during the 1990s but increased by 6 years between 2000-2004 and 2005-2009. Survival of patients with Alport syndrome requiring dialysis or transplantation did not change between 1990 and 2009. However, patients with Alport syndrome had better renal graft and patient survival than matched controls. Numbers of living-donor transplantations were lower in patients with Alport syndrome than in matched controls. CONCLUSIONS: These data suggest that kidney failure in patients with Alport syndrome is now being delayed compared with previous decades. These patients appear to have superior patient survival while undergoing dialysis and superior patient and graft survival after deceased-donor kidney transplantation compared with patients receiving RRT because of other causes of kidney failure
MP215ACUTE RENAL FAILURE SECONDARY TO RENINE ANGIOTENSIN SYSTEM BLOKERS SHORT AND LONG TERM PROGNOSIS
No full textMultinational observational study on clinical practices and therapeutic management of mineral and bone disorders in patients with chronic kidney disease stages 4, 5, and 5D: The OCEANOS study
No full textOur aim is to assess the current clinical practices in monitoring and treatment patterns of chronic kidney disease (CKD)-mineral bone disorder and the degree to which these practices met the kidney disease improving global outcome (KDIGO) guidelines. This was an international, multi-center, cross-sectional, observational study in adult patients diagnosed with CKD Stages 4, 5, and 5D. Patients were enrolled from Middle East, South Asia, Eurasia, and Africa; patients with estimated glomerular filtration rate ≥30 mL/min/1.73 m 2 or with any medical/surgical conditions precluding their participation were excluded. Frequency of measurements, levels of serum calcium (Ca), phosphorus and parathormone (parathyroid hormone [PTH], and presence vascular/valvular calcification were recorded. Of the 2250 patients enrolled, data on 2247 patients were evaluated. Overall, only a small percentage of patients met all three target KDIGO ranges of serum Ca, phosphorus, and PTH (13.7% [95% confidence interval: 12.0; 15.4], with a higher proportion among CKD Stage 5D patients (14.8%) than CKD Stage 4 and 5 (5.6%) patients. Majority (84.3%) of the patients received treatment with phosphorous binders, of whom 85.5% received Ca-based phosphate binders. Overall, 57.0% of patients received Vitamin D treatment with a similar frequency among patients with CKD Stages 4, 5, and 5D. Over half (65.7%) of the patients were screened for vascular/valvular calcification; of these, 58.8% had ≥1 calcification. Diabetes status, P, PTH, and low density lipoprotein-cholesterol had significant impact on the prescription pattern of phosphorous binders. The current practices for the management of bone and mineral metabolism in CKD patients in the study region fall far short of meeting the KDIGO target range
Profil épidémiologique de l’insuffisance rénale chronique terminale dans la région de Sfax
No full textIntroduction: L'insuffisance rénale chronique terminaleest un véritable problème mondial de Santé publique. En Tunisie, le coût de la prise en charge des patients dialysés pour l'année 2011 a dépassé les 90 millions de dinars (37000 Euro), soit près de 5% des dépenses globales de santé. Une meilleure connaissance du profil épidémiologique de l'insuffisance rénale chronique terminale va contribuer à l'élaboration et à l'évaluation des stratégies sanitaires visant à améliorer la prévention et la prise en charge de cette maladie. L'objectif de notre travail est de décrire le profil épidémiologique des cas incidents dans le gouvernorat de Sfax sur une période de 10 ans. Méthodes: Il s'agit d'une étude descriptive rétrospective allant de Janvier 2003 à Décembre 2012. Nous avons inclus les cas incidents d'insuffisance rénale chronique terminale dans le gouvernorat de Sfax. Résultats: Le diagnostic d'insuffisance rénale chronique terminale a été porté à 1708 cas. Il s'agit de 957 hommes et 751 femmes (sex-ratio = 1,27). L'âge moyen était de 58,4ans [10-100ans]. L'étude de l'évolution de l'âge moyen durant la période étudiée a montré une tendance vers la hausse avec un indice de corrélation positive (0,749) et p = 0,006. La principale néphropathie causale était la néphropathie diabétique (21,5%), avec une augmentation significative de sa fréquence d'une année à l'autre (un coefficient de corrélation positive (0,770) avec p = 0,009). L'hémodialyse était la technique de dialyse de choix, entreprise chez 96% des patients. Conclusion: Un registre national reste indispensable afin de mieux comprendre le profil épidémiologique de l'insuffisance rénale chronique terminale en Tunisie et de pouvoir améliorer sa prise en charge
Profil épidémiologique de l'insuffisance rénale chronique terminale dans la région de Sfax
No full text
